Taysha Gene Therapies
TSHA· Manufacturing· Fiscal year ends in December
CEO pay in FY2022Stock -80.6% in FY2022
Sean Nolan is the CEO of Taysha Gene Therapies and was paid $1.9M in FY2022 (Dec).
Pay$100 in the stock at the end of FY21 → $4
Executives3
See all- 1Kamran AlamChief Financial OfficerFY2024
- 2Sean NolanChief Executive Officer and DirectorFY2022
- 3Sukumar Nagendran, M.D.President and Head of Research and Development and DirectorFY2022
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allTaysha Gene Therapies paid its one named executive on file $2.5M in FY2024 (Dec).
| Name | |||
|---|---|---|---|
| Kamran AlamChief Financial Officer | |||
| Sean NolanChief Executive Officer and Director | Not disclosed | Not disclosed | |
| Sukumar Nagendran, M.D.President and Head of Research and Development and Director | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Taysha Gene Therapies. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Board5
See all- Laura Sepp-Lorenzino, Ph.D.Director · 5 yr on the boardIndependentAudit, Clinical and Scientific, Compensation—Paid as an executive
- Phillip B. DonenbergDirector · 5 yr on the boardIndependentAudit, Compensation—Paid as an executive
- Sukumar Nagendran, M.D.Director · 5 yr on the boardNot independent—Paid as an executive
- Alison LongDirector · 2 yr on the boardIndependentClinical and Scientific, Compensation, Nominating and Corporate Governance—Paid as an executive
- Sean StalfortDirector · 2 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 22, 2026 | FY2025 |
| Annual report | 10-K | Mar 19, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 21, 2025 | FY2024 |
| Annual report | 10-K | Feb 26, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 18, 2024 | FY2023 |
| Annual report | 10-K | Mar 19, 2024 | FY2023 |
